SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based ...
"Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a protective gel with a mechanical action indicated for the management of pain ...
The Food and Drug Administration agreed to speed up the review of avasopasem to treat severe oral mucositis in patients with head and neck cancer. The Food and Drug Administration (FDA) granted a ...
Jaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US market
Jaguar Health, Inc. announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC (Venture Life), an international consumer health company ...
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients ...
Sinopia Awarded Grant from National Institute of Dental and Craniofacial Research for Oral Mucositis
Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a grant from the National ...
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for ...
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results